Premium
Nedocromil sodium is more potent than sodium cromoglycate against AMP‐induced bronchoconstriction in atopic asthmatic subjects
Author(s) -
RICHARDS R.,
PHILLIPS G. D.,
HOLGATE S. T.
Publication year - 1989
Publication title -
clinical and experimental allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.462
H-Index - 154
eISSN - 1365-2222
pISSN - 0954-7894
DOI - 10.1111/j.1365-2222.1989.tb02385.x
Subject(s) - nedocromil sodium , bronchoconstriction , inhalation , provocation test , placebo , nedocromil , asthma , medicine , sodium , cromolyn sodium , pharmacology , sodium cromoglycate , chemistry , anesthesia , endocrinology , alternative medicine , organic chemistry , pathology
Summary Nedocromil sodium is a new chemical entity which shows similar properties to sodium cromoglycate (SCG) and in addition exhibits a preferential activity in stabilizing mucosal mast cells. We have compared the effect of inhalation of nebulized placebo, SCG and nedocromil sodium on the bronchoconstrictor response to inhaled adenosine monophosphate (AMP) in eight atopic asthmatic subjects aged 25 yr (range 21–32 yr). The geometric mean provocation doses of AMP required to produce a 20% decrease in FEV 1 (PD 20 FEV 1 ) and a 40% decrease in V˙max 30 (PD 40 V˙max 30 ) following placebo were 4.9 (0.3–14.2) and 1.8 (0.1–8.4) μmol respectively. Prior inhalation of both SCG and nedocromil sodium significantly inhibited the bronchoconstrictor response to AMP with PD 20 FEV 1 s of 36.6 (4.0–132.7) and 134 (12.4–560), and PD 40 V˙max 30 values of 20.5 (1.4–110) and 101.6 (5–560) μmol respectively ( P <0.001). Nedocromil sodium was 3.9 (FEV 1 ) and 8.0 (Vmax 30 ) times more potent than SCG ( P <0.001). In conclusion, both drugs inhibit the bronchoconstrictor response to inhaled AMP, and nedocromil is at least 4–8 times more potent than SCG.